Literature DB >> 30058704

Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice.

D-D Huang1, H-F Huang, Q Yang, X-Q Chen.   

Abstract

OBJECTIVE: To study the role and mechanism of liraglutide in myocardial fibrosis after myocardial infarction (MI).
MATERIALS AND METHODS: A total of 72 C57/BL male mice were randomly divided into sham operation group (Sham group), myocardial infarction group (MI group), and liraglutide intervention group (Lira group). The left anterior descending coronary artery (LAD) of the mice in MI group and Lira group was ligated to establish the MI model. One week after the operation, the mice in Lira group were intraperitoneally injected with 100 μg/kg of liraglutide once a day for 4 weeks. The mice in Sham group and MI group were injected with the equal volume of normal saline. At the 5th week after the operation, the cardiac morphologic indexes and cardiac function indexes were measured by echocardiography. After an ultrasound, the heart specimens of the mice were immediately harvested by thoracotomy, and histomorphological hematoxylin-eosin (HE) staining, collagen fiber Masson staining, and immunohistochemical staining were performed. The infarction zone and the non-infarction zone were isolated from another heart specimen; the cyclic adenosine monophosphate (cAMP) and hydroxyproline content were determined; and the expression levels of transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) were detected by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Western blotting.
RESULTS: Liraglutide improved the cardiac function of mice after myocardial infarction. Liraglutide improved the myocardial fibrosis in mice after myocardial infarction. Liraglutide increased cAMP in myocardial cells of mice after myocardial infarction. Liraglutide did not change the TGF-β1 expressions while reduced the CTGF expressions in infarct and non-infarct area of mice after myocardial infarction.
CONCLUSIONS: Liraglutide, through increasing the level of cAMP, could decrease the deposition of collagen fibers in myocardial tissues of mice after MI, reduce the degree of infiltration of collagen fibers in the infarction zone into the myocardium in the non-infarction zone and inhibit the adverse ventricular remodeling in the non-infarction zone, thus improving the cardiac function after MI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30058704     DOI: 10.26355/eurrev_201807_15524

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury.

Authors:  Chong Liu; Yong Liu; Jing He; Rong Mu; Yanbo Di; Na Shen; Xuan Liu; Xiao Gao; Jinhui Wang; Tie Chen; Tao Fang; Huanming Li; Fengshi Tian
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

2.  Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.

Authors:  Anna Simanenkova; Sarkis Minasian; Tatiana Karonova; Timur Vlasov; Natalya Timkina; Oksana Shpilevaya; Aleksandra Khalzova; Anzhelika Shimshilashvili; Valeria Timofeeva; Daniil Samsonov; Yury Borshchev; Michael Galagudza
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

3.  Knock out hepatic Krüppel-like factor 16 (KLF16) improve myocardial damage and promoted myocardial protection of myocardial ischemia-reperfusion via anti-oxidative and anti-inflammation effects by TFAM/PPARβ signal passage.

Authors:  Yue Xin; Pixiong Su; Yan Liu; Song Gu; Xiangguang An; Xitao Zhang; Jun Yan; Yulin Guo; Jian Zhou; Guilin Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Tranilast inhibits angiotensin II-induced myocardial fibrosis through S100A11/ transforming growth factor-β (TGF-β1)/Smad axis.

Authors:  Youquan Chen; Ming Huang; Yi Yan; Dequan He
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Cilostazol Attenuates AngII-Induced Cardiac Fibrosis in apoE Deficient Mice.

Authors:  Yoshiko Hada; Haruhito A Uchida; Ryoko Umebayashi; Masashi Yoshida; Jun Wada
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

6.  Effects of liraglutide vs. lifestyle changes on soluble suppression of tumorigenesis-2 (sST2) and galectin-3 in obese subjects with prediabetes or type 2 diabetes after comparable weight loss.

Authors:  Paola Simeone; Romina Tripaldi; Annika Michelsen; Thor Ueland; Rossella Liani; Sonia Ciotti; Kåre I Birkeland; Hanne L Gulseth; Augusto Di Castelnuovo; Francesco Cipollone; Pål Aukrust; Agostino Consoli; Bente Halvorsen; Francesca Santilli
Journal:  Cardiovasc Diabetol       Date:  2022-03-11       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.